Literature DB >> 11049800

Short-course of oral miltefosine for treatment of visceral leishmaniasis.

S Sundar1, A Makharia, D K More, G Agrawal, A Voss, C Fischer, P Bachmann, H W Murray.   

Abstract

A total of 54 Indian patients with visceral leishmaniasis were treated with oral miltefosine, 50 mg given twice daily, for 14 days (18 patients; group A), 21 days (18; group B), or 28 days (18; group C). Cure was achieved in 89% of group A, 100% of group B, and 100% of group C. Adverse reactions were self-limited and primarily mild. The 21-day miltefosine regimen combines high-level efficacy, convenient dosing, and a relatively short duration.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11049800     DOI： 10.1086/318122

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  40 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.

Authors:  Victor B Saraiva; Daniel Gibaldi; José O Previato; Lucia Mendonça-Previato; Marcelo T Bozza; Célio G Freire-De-Lima; Norton Heise
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis.

Authors:  Richard D. Pearson
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

4.  Immunomodulatory and Antileishmanial Activity of Phenylpropanoid Dimers Isolated from Nectandra leucantha.

Authors:  Thais Alves da Costa-Silva; Simone S Grecco; Fernanda S de Sousa; João Henrique G Lago; Euder G A Martins; César A Terrazas; Sanjay Varikuti; Katherine L Owens; Stephen M Beverley; Abhay R Satoskar; Andre G Tempone
Journal:  J Nat Prod       Date:  2015-04-02       Impact factor: 4.050

5.  Leishmania tarentolae: purification and characterization of tubulin and its suitability for antileishmanial drug screening.

Authors:  Adam J Yakovich; Frank L Ragone; Juan D Alfonzo; Dan L Sackett; Karl A Werbovetz
Journal:  Exp Parasitol       Date:  2006-06-05       Impact factor: 2.011

6.  Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.

Authors:  Marta Mateo; Laurence Maynard; Claudia Vischer; Paolo Bianciardi; Guadalupe Miró
Journal:  Parasitol Res       Date:  2009-02-24       Impact factor: 2.289

7.  Miltefosine (Impavido): the first oral treatment against leishmaniasis.

Authors:  H Sindermann; S L Croft; K R Engel; W Bommer; H J Eibl; C Unger; J Engel
Journal:  Med Microbiol Immunol       Date:  2003-09-26       Impact factor: 3.402

8.  Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug.

Authors:  María P Sánchez-Cañete; Luís Carvalho; F Javier Pérez-Victoria; Francisco Gamarro; Santiago Castanys
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

9.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05

10.  Deep-sequencing revealing mutation dynamics in the miltefosine transporter gene in Leishmania infantum selected for miltefosine resistance.

Authors:  Marie-Claude N Laffitte; Philippe Leprohon; Danielle Légaré; Marc Ouellette
Journal:  Parasitol Res       Date:  2016-07-26       Impact factor: 2.289
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.